Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL10006506 | 0.87 | CA1 (0.36) | ESR1ALB | |
| Methacrylic Acid SCHEMBL17595443 | 0.84 | ESR1 (0.33) | ESR1 | |
| Acetic Acid Methyl Ester SCHEMBL5270932 | 0.80 | ALDH1A1 (0.53) | ESR1 | |
| Trifluoroacetic Acid SCHEMBL1274530 | 0.77 | CES1 (0.32) | ESR1 | |
| SCHEMBL9040401 | 0.77 | ESR1 (0.44) | ESR1 | |
| SCHEMBL1626967 | 0.76 | ESR1 (0.32) | ESR1 | |
| Tetrafluororesorcinol SCHEMBL123852 | 0.75 | ESR1 (0.30) | ESR1 | |
| SCHEMBL1960786 | 0.75 | ESR1 (0.30) | ESR1 | |
| SCHEMBL390508 | 0.75 | ESR1 (0.30) | ESR1 | |
| SCHEMBL2121680 | 0.75 | ESR1 (0.30) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552125-A | Compounds and compositions for ocular treatment | 艾弗德罗股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-114072149-B | Compounds and compositions for ocular treatment | 艾弗德罗股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114072149-A | Compounds and compositions for ocular treatment | 艾弗德罗股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-RE46171-E1 | Functional biopolymer modification reagents and uses thereof | SOLULINK, INCORPORATED (US) | 2016-10-04 | — | — | US | disclosed |
| US-7732628-B2 | Such as 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]benzaldehyde, 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]acetophenone; for incorporation into oligonucleotides during immobilization and conjugation of biopolymers in solid phase synthesis | SOLULINK INCORPORATED (US) | 2010-06-08 | — | — | US | disclosed |
| US-7102024-B1 | Functional biopolymer modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2006-09-05 | — | — | US | disclosed |
| US-20050203289-A1 | Functional biopolymer modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2005-09-15 | — | — | US | disclosed |
| CN-1062355-A | Catalyst composition and the method for preparing polymkeric substance | SHELL INT RESEARCH (NL) | 1992-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203289-A1 | Functional biopolymer modification reagents and uses thereof | OGG1, OGA, HMOX2 | ESR1 2504/4885FFAR3 3273/4885LCK 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.